Trial reportClinical autonomic research : official journal of the Clinical Autonomic Research Society2011
An alternative to treat palmar hyperhidrosis: use of oxybutynin.
Trial report in Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01956591 (Retrospective Evaluation of Long Term Use of Oxybutynin in the Pharmacological Treatment of Primary Hyperhidrosis), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retrospective Evaluation of Long Term Use of Oxybutynin in the Pharmacological Treatment of Primary Hyperhidrosis
Who cites it
14 citing papers in PubMed, 59 citations in OpenAlex.
- Long-term results of oxybutynin treatment for palmar hyperhidrosis.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2014Trial
- The use of an objective method (continuous exosomatic electrodermal activity without external stimuli) to evaluate patients with hyperhidrosis undergoing video-assisted sympathectomy.Einstein (Sao Paulo, Brazil) · 2026Article
- Efficacy and Safety of Treatments for Primary Palmar Hyperhidrosis: A Systematic Review Assessing Patient-Centric Outcomes.Dermatology research and practice · 2025Review
- Effectiveness of unilateral sequential video-assisted sympathetic chain blockage for primary palmar hyperidrosis in children and adolescents.Frontiers in pediatrics · 2022Article
- Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions.Clinical, cosmetic and investigational dermatology · 2019Article
- Atypical aquagenic keratoderma treated with oxybutynin chloride.Anais brasileiros de dermatologia · 2018Article
- Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art.Skin appendage disorders · 2015Review
- Treatment of uncommon sites of focal primary hyperhidrosis: experience with pharmacological therapy using oxybutynin.Clinics (Sao Paulo, Brazil) · 2014Article
- Management of hyperhidrosis.Clinical, cosmetic and investigational dermatology · 2014Review
- Analysis of oxybutynin treatment for hyperhidrosis in patients aged over 40 years.Einstein (Sao Paulo, Brazil)Article
- Long-term results of oxybutynin use in treating facial hyperhidrosis.Anais brasileiros de dermatologiaArticle
- Population-based analysis of the epidemiology of the surgical correction of hyperhidrosis in 1,216 patients over 11 years: a cross-sectional study.Sao Paulo medical journal = Revista paulista de medicinaArticle
- Efficacy, Safety and Quality of Life of Oxybutynin versus Aluminum Chloride Hexahydrate in Treating Primary Palmar Hyperhidrosis.Indian journal of dermatologyArticle
- Oxybutynin as an alternative treatment for hyperhidrosis.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effectiveness and patient satisfaction with the use of oxybutynin at low doses for treating palmar hyperhidrosis in a large series of patients.
methodsFrom January 2007 to June 2009, 180 consecutive patients with palmar hyperhidrosis were treated with oxybutynin. Data were collected from 139 patients (41 patients were lost to follow-up). During the first week, patients received 2.5 mg of oxybutynin once per day; from the 8th to the 42nd day, 2.5 mg twice per day; and from the 43rd day to the end of the 12th week, 5 mg, twice per day. All of the patients underwent three evaluations before and after the oxybutynin treatment (at 6 and 12 weeks), using a clinical questionnaire and a clinical protocol for quality of life (QOL).
resultsMore than 80% of the patients experienced an improvement in palmar hyperhidrosis. Most of the patients showed improvements in their QOL (74.6%). The side effects were minor, with dry mouth being the most frequent (70.5%).
conclusionThe use of oxybutynin is an alternative as the first step in the treatment of palmar hyperhidrosis, given that it presents good results and improves QOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.